Skip to main content
SpringerLink
Log in

Hematologic Disorders

  • Living reference work entry
  • First Online:
Geriatric Medicine

  • 24 Accesses

Abstract

Hematologic disorders are a diverse group of malignant and nonmalignant conditions arising from the blood and other hematopoietic sources. Many of the malignant disorders (myelodysplastic syndrome, multiple myeloma, and myeloproliferative neoplasms) are clonal in nature and occur with increasing frequency in older adults (aged ≥65 years). The prevalence of anemia also increases with advancing age. Importantly for older adults, the causes of anemia are many, resulting from chronic diseases, inflammatory conditions, and nutritional deficiencies, which may coexist therefore making the diagnosis difficult. As the global number of older adults continues to rapidly expand, the prevalence and incidence of hematologic disorders are also expected to increase. Thus, there is a need to refine the approaches to diagnosis and management of hematologic disorders to include strategies which account for the intersection of aging and hematology. Such an approach would involve assessment of patient fitness through the use of geriatric assessments, which may then be used to tailor an appropriate individualized management plan for an older adult. Furthermore, such an approach accounts for the heterogeneity of aging while incorporating patient preferences. Use of a personalized approach for the management of hematologic disorders could improve disease-related outcomes, especially for those considered less fit or frail, while minimizing treatment-related toxicities and preserving quality-of-life.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

References

  1. Coulson AB, Royle KL, Pawlyn C, Cairns DA, Hockaday A, Bird J, Bowcock S, Kaiser M, de Tute R, Rabin N, Boyd K, Jones J, Parrish C, Gardner H, Meads D, Dawkins B, Olivier C, Henderson R, Best P, Owen R, Jenner M, Kishore B, Drayson M, Jackson G, Cook G. Frailty-adjusted therapy in Transplant Non-Eligible patients with newly diagnosed Multiple Myeloma (FiTNEss (UK-MRA Myeloma XIV Trial)): a study protocol for a randomised phase III trial. BMJ Open. 2022;12(6):e056147. https://doi.org/10.1136/bmjopen-2021-056147. PMID: 35654466; PMCID: PMC9163533

  2. Culleton BF, Manns BJ, Zhang JG, Tonelli M, Klarenbach S, Hemmelgarn BR. Impact of anemia on hospitalization and mortality in older adults. Blood. 2006;107(10):3841–6.

    Article  CAS  PubMed  Google Scholar 

  3. Juarez-Cedillo T, Basurto-Acevedo L, Vega-Garcia S, Manuel-Apolinar L, Cruz-Tesoro E, Rodriguez-Perez JM, et al. Prevalence of anemia and its impact on the state of frailty in elderly people living in the community: SADEM study. Ann Hematol. 2014;93(12):2057–62.

    Article  CAS  PubMed  Google Scholar 

  4. Lucca U, Tettamanti M, Mosconi P, Apolone G, Gandini F, Nobili A, et al. Association of mild anemia with cognitive, functional, mood and quality of life outcomes in the elderly: the “health and anemia” study. PLoS One. 2008;3(4):e1920.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Shavelle RM, MacKenzie R, Paculdo DR. Anemia and mortality in older persons: does the type of anemia affect survival? Int J Hematol. 2012;95(3):248–56.

    Article  PubMed  Google Scholar 

  6. Boyd CM, Darer J, Boult C, Fried LP, Boult L, Wu AW. Clinical practice guidelines and quality of care for older patients with multiple comorbid diseases – implications for pay for performance. JAMA. 2005;294(6):716–24.

    Article  CAS  PubMed  Google Scholar 

  7. United Nations World Population Prospects 2019 [cited 2020]. Available from: https://population.un.org/wpp/Graphs/DemographicProfiles/Pyramid/900

  8. Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391–405.

    Article  CAS  PubMed  Google Scholar 

  9. Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener J, et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci. 2001;56(3):M146–56.

    Article  CAS  PubMed  Google Scholar 

  10. Rockwood K, Howlett SE, MacKnight C, Beattie BL, Bergman H, Hebert R, et al. Prevalence, attributes, and outcomes of fitness and frailty in community-dwelling older adults: report from the Canadian study of health and aging. J Gerontol A Biol Sci Med Sci. 2004;59(12):1310–7.

    Article  PubMed  Google Scholar 

  11. Hamaker ME, Prins MC, Stauder R. The relevance of a geriatric assessment for elderly patients with a haematological malignancy – a systematic review. Leuk Res. 2014;38(3):275–83.

    Article  CAS  PubMed  Google Scholar 

  12. WHO. Nutritional anaemias. Report of a WHO scientific group. World Health Organization technical report series, vol. 405. Geneva: WHO; 1968. p. 5–37.

    Google Scholar 

  13. Lopez-Otin C, Blasco MA, Partridge L, Serrano M, Kroemer G. The hallmarks of aging. Cell. 2013;153(6):1194–217.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Beutler E, Waalen J. The definition of anemia: what is the lower limit of normal of the blood hemoglobin concentration? Blood. 2006;107(5):1747–50.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Guralnik JM, Eisenstaedt RS, Ferrucci L, Klein HG, Woodman RC. Prevalence of anemia in persons 65 years and older in the United States: evidence for a high rate of unexplained anemia. Blood. 2004;104(8):2263–8.

    Article  CAS  PubMed  Google Scholar 

  16. Patel KV. Epidemiology of anemia in older adults. Semin Hematol. 2008;45(4):210–7.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Gaskell H, Derry S, Andrew Moore R, McQuay HJ. Prevalence of anaemia in older persons: systematic review. BMC Geriatr. 2008;8:1.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Joosten E, Lioen P. Iron deficiency anemia and anemia of chronic disease in geriatric hospitalized patients: how frequent are comorbidities as an additional explanation for the anemia? Geriatr Gerontol Int. 2015;15(8):931–5.

    Article  PubMed  Google Scholar 

  19. Chaves PHM, Xue QL, Guralnik JM, Ferrucci L, Volpato S, Fried LP. What constitutes normal hemoglobin concentration in community-dwelling disabled older women? J Am Geriatr Soc. 2004;52(11):1811–6.

    Article  PubMed  Google Scholar 

  20. Izaks GJ, Westendorp RGJ, Knook DL. The definition of anemia in older persons. JAMA. 1999;281(18):1714–7.

    Article  CAS  PubMed  Google Scholar 

  21. Penninx B, Guralnik JM, Onder G, Ferrucci L, Wallace RB, Pahor M. Anemia and decline in physical performance among older persons. Am J Med. 2003;115(2):104–10.

    Article  PubMed  Google Scholar 

  22. den Elzen WPJ, Willems JM, Westendorp RGJ, de Craen AJM, Assendelft WJJ, Gussekloo J. Effect of anemia and comorbidity on functional status and mortality in old age: results from the Leiden 85-plus study. Can Med Assoc J. 2009;181(3–4):151–7.

    Article  Google Scholar 

  23. Chaves PHM, Ashar B, Guralnik JM, Fried LP. Looking at the relationship between hemoglobin concentration and prevalent mobility difficulty in older women. Should the criteria currently used to define anemia in older people be reevaluated? J Am Geriatr Soc. 2002;50(7):1257–64.

    Article  PubMed  Google Scholar 

  24. Chaves PHM, Carlson MC, Ferrucci L, Guralnik JM, Semba R, Fried LP. Association between mild anemia and executive function impairment in community-dwelling older women: the women’s health and aging study II. J Am Geriatr Soc. 2006;54(9):1429–35.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Penninx B, Pahor M, Cesari M, Corsi AM, Woodman RC, Bandinelli S, et al. Anemia is associated with disability and decreased physical performance and muscle strength in the elderly. J Am Geriatr Soc. 2004;52(5):719–24.

    Article  PubMed  Google Scholar 

  26. Penninx B, Pluijm SMF, Lips P, Woodman R, Miedema K, Guralnik JM, et al. Late-life anemia is associated with increased risk of recurrent falls. J Am Geriatr Soc. 2005;53(12):2106–11.

    Article  PubMed  Google Scholar 

  27. Chaves PHM, Semba RD, Leng SX, Woodman RC, Ferrucci L, Guralnik JM, et al. Impact of anemia and cardiovascular disease on frailty status of community-dwelling older women: the women’s health and aging studies I and II. J Gerontol A Biol Sci Med Sci. 2005;60(6):729–35.

    Article  PubMed  Google Scholar 

  28. Semba RD, Ricks MO, Ferrucci L, Xue QL, Chaves P, Fried LP, et al. Types of anemia and mortality among older disabled women living in the community: the women’s health and aging study I. Aging Clin Exp Res. 2007;19(4):259–64.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Weiss G, Ganz T, Goodnough LT. Anemia of inflammation. Blood. 2019;133(1):40–50.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Priya PP, Subhashree AR. Role of absolute reticulocyte count in evaluation of pancytopenia-a hospital based study. J Clin Diagn Res. 2014;8(8):FC01–3.

    Google Scholar 

  31. Docherty AB, Turgeon AF, Walsh TS. Best practice in critical care: anaemia in acute and critical illness. Transfus Med. 2018;28(2):181–9.

    Article  CAS  PubMed  Google Scholar 

  32. Dandrea AD, Lodish HF, Wong GG. Expression cloning of the murine erythropoietin receptor. Cell. 1989;57(2):277–85.

    Article  CAS  PubMed  Google Scholar 

  33. Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, et al. A trial of Darbepoetin Alfa in type 2 diabetes and chronic kidney disease. N Engl J Med. 2009;361(21):2019–32.

    Article  PubMed  Google Scholar 

  34. Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med. 1998;339(9):584–90.

    Article  CAS  PubMed  Google Scholar 

  35. Drueke TB, Locatelli F, Clyne N, Eckardt K, Macdougall IC, Tsakiris D, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med. 2006;355(20):2071–84.

    Article  CAS  PubMed  Google Scholar 

  36. Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006;355(20):2085–98.

    Article  CAS  PubMed  Google Scholar 

  37. Girelli D, Ugolini S, Busti F, Marchi G, Castagna A. Modern iron replacement therapy: clinical and pathophysiological insights. Int J Hematol. 2018;107(1):16–30.

    Article  CAS  PubMed  Google Scholar 

  38. Theurl M, Nairz M, Schroll A, Sonnweber T, Asshoff M, Haschka D, et al. Hepcidin as a predictive factor and therapeutic target in erythropoiesis-stimulating agent treatment for anemia of chronic disease in rats. Haematologica. 2014;99(9):1516–24.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Haase VH. Therapeutic targeting of the HIF oxygen-sensing pathway: lessons learned from clinical studies. Exp Cell Res. 2017;356(2):160–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Andres E, Zulfiqar AA, Serraj K, Vogel T, Kaltenbach G. Systematic review and pragmatic clinical approach to Oral and nasal vitamin B12 (cobalamin) treatment in patients with vitamin B12 deficiency related to gastrointestinal disorders. J Clin Med. 2018;7(10):13.

    Article  Google Scholar 

  41. Andres E, Vidal-Alaball J, Federici L, Loukili NH, Zimmer J, Kaltenbach G. Clinical aspects of cobalamin deficiency in elderly patients. Epidemiology, causes, clinical manifestations, and treatment with special focus on oral cobalamin therapy. Eur J Intern Med. 2007;18(6):456–62.

    Article  CAS  PubMed  Google Scholar 

  42. Valuck RJ, Ruscin JM. A case-control study on adverse effects: H2 blocker or proton pump inhibitor use and risk of vitamin B-12 deficiency in older adults. J Clin Epidemiol. 2004;57(4):422–8.

    Article  PubMed  Google Scholar 

  43. Bizzaro N, Antico A. Diagnosis and classification of pernicious anemia. Autoimmun Rev. 2014;13(4–5):565–8.

    Article  PubMed  Google Scholar 

  44. Stabler SP. Vitamin B-12 deficiency. N Engl J Med. 2013;368(2):149–60.

    Article  CAS  PubMed  Google Scholar 

  45. Mohamed M, Thio J, Thomas RS, Phillips J. Pernicious anaemia. BMJ. 2020;369:m1319.

    Article  PubMed  Google Scholar 

  46. Devalia V, Hamilton MS, Molloy AM, British Committee for Standards in Haematology. Guidelines for the diagnosis and treatment of cobalamin and folate disorders. Br J Haematol. 2014;166(4):496–513.

    Article  CAS  PubMed  Google Scholar 

  47. Green R. Vitamin B-12 deficiency from the perspective of a practicing hematologist. Blood. 2017;129(19):2603–11.

    Article  CAS  PubMed  Google Scholar 

  48. Sukumar N, Saravanan P. Investigating vitamin B12 deficiency. BMJ. 2019;365:11865.

    Google Scholar 

  49. Wang HY, Li LY, Qin LL, Song YN, Vidal-Alaball J, Liu TH. Oral vitamin B-12 versus intramuscular vitamin B-12, for vitamin B-12 deficiency. Cochrane Database Syst Rev. 2018;3:CD004655.

    PubMed  Google Scholar 

  50. Vasconcelos OM, Poehm EH, McCarter RJ, Campbell WW, Quezado ZMN. Potential outcome factors in subacute combined degeneration – review of observational studies. J Gen Intern Med. 2006;21(10):1063–8.

    Article  PubMed  PubMed Central  Google Scholar 

  51. Murphy G, Dawsey SM, Engels EA, Ricker W, Parsons R, Etemadi A, et al. Cancer risk after pernicious anemia in the US Elderly Population. Clin Gastroenterol Hepatol. 2015;13(13):2282.

    Article  PubMed  PubMed Central  Google Scholar 

  52. Hurrell R, Egli I. Iron bioavailability and dietary reference values. Am J Clin Nutr. 2010;91(5):1461S–7S.

    Article  CAS  PubMed  Google Scholar 

  53. Price EA, Mehra R, Holmes TH, Schrier SL. Anemia in older persons: etiology and evaluation. Blood Cells Mol Dis. 2011;46(2):159–65.

    Article  CAS  PubMed  Google Scholar 

  54. Yavuz BB, Cankurtaran M, Haznedaroglu IC, Halil M, Ulger Z, Altun B, et al. Iron deficiency can cause cognitive impairment in geriatric patients. J Nutr Health Aging. 2012;16(3):220–4.

    Article  CAS  PubMed  Google Scholar 

  55. Schultz BM, Freedman ML. Iron deficiency in the elderly. Baillieres Clin Haematol. 1987;1(2):291–313.

    Article  CAS  PubMed  Google Scholar 

  56. Joosten E, Hiele M, Ghoos Y, Pelemans W, Boogaerts MA. Diagnosis of iron-deficiency anemia in a hospitalized geriatric population. Am J Med. 1991;90(5):653–4.

    Article  CAS  PubMed  Google Scholar 

  57. Nahon S, Lahmek P, Aras N, Poupardin C, Lesgourgues R, Macaigne G, et al. Management and predictors of early mortality in elderly patients with iron deficiency anemia: a prospective study of 111 patients. Gastroenterol Clin Biol. 2007;31(2):169–74.

    Article  PubMed  Google Scholar 

  58. Joosten E, Ghesquiere B, Linthoudt H, Krekelberghs F, Dejaeger E, Boonen S, et al. Upper and lower gastrointestinal evaluation of elderly inpatients who are iron deficient. Am J Med. 1999;107(1):24–9.

    Article  CAS  PubMed  Google Scholar 

  59. Zeidan AM, Shallis RM, Wang R, Davidoff A, Ma XM. Epidemiology of myelodysplastic syndromes: why characterizing the beast is a prerequisite to taming it. Blood Rev. 2019;34:1–15.

    Article  PubMed  Google Scholar 

  60. Sallman DA, List A. The central role of inflammatory signaling in the pathogenesis of myelodysplastic syndromes. Blood. 2019;133(10):1039–48.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. Welch JS, Ley TJ, Link DC, Miller CA, Larson DE, Koboldt DC, et al. The origin and evolution of mutations in acute myeloid leukemia. Cell. 2012;150(2):264–78.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  62. Jaiswal S, Fontanillas P, Flannick J, Manning A, Grauman PV, Mar BG, et al. Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med. 2014;371(26):2488–98.

    Article  PubMed  PubMed Central  Google Scholar 

  63. Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Sole F, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120(12):2454–65.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  64. Bammer C, Sperr WR, Kemmler G, Wimazald F, Nosslinger T, Schonmetzler A, et al. Clustering of comorbidides is related to age and sex and impacts clinical outcome in myelodysplastic syndromes. J Geriatr Oncol. 2014;5(3):299–306.

    Article  PubMed  Google Scholar 

  65. Della Porta MG, Malcovati L, Strupp C, Ambaglio I, Kuendgen A, Zipperer E, et al. Risk stratification based on both disease status and extra-hematologic comorbidities in patients with myelodysplastic syndrome. Haematologica. 2011;96(3):441–9.

    Article  PubMed  Google Scholar 

  66. Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005;106(8):2912–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  67. Rockwood K, Song XW, MacKnight C, Bergman H, Hogan DB, McDowell I, et al. A global clinical measure of fitness and frailty in elderly people. Can Med Assoc J. 2005;173(5):489–95.

    Article  Google Scholar 

  68. Morley JE, Malmstrom TK, Miller DK. A simple frailty questionnaire (FRAIL) predicts outcomes in middle aged African Americans. J Nutr Health Aging. 2012;16(7):601–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  69. Luskin MR, Abel GA. Management of older adults with myelodysplastic syndromes (MDS). J Geriatr Oncol. 2018;9(4):302–7.

    Article  PubMed  Google Scholar 

  70. Pallera A, Altman JK, Berman E, Abboud CN, Bhatnagar B, Curtin P, et al. NCCN guidelines (R) insights chronic myeloid leukemia, version 1.2017 featured updates to the NCCN guidelines. J Natl Compr Cancer Netw. 2016;14(12):1505–12.

    Article  CAS  Google Scholar 

  71. Haouala A, Widmer N, Duchosal MA, Montemurro M, Buclin T, Decosterd LA. Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib. Blood. 2011;117(8):E75–87.

    Article  CAS  PubMed  Google Scholar 

  72. Jabbour E, Makenbaeva D, Lingohr-Smith M, Lin J. Use of real-world claim databases to assess prevalence of comorbid conditions relevant to the treatment of chronic myelogenous leukemia based on national comprehensive network treatment guidelines. Clin Lymphoma Myeloma Leuk. 2015;15(12):797.

    Article  PubMed  Google Scholar 

  73. Srour SA, Devesa SS, Morton LM, Check DP, Curtis RE, Linet MS, et al. Incidence and patient survival of myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms in the United States, 2001–12. Br J Haematol. 2016;174(3):382–96.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  74. Barbui T, Vannucchi AM, Buxhofer-Ausch V, De Stefano V, Betti S, Rambaldi A, et al. Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia. Blood Cancer J. 2015;5:e369.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  75. Samuelson S, Sandmaier BM, Heslop HE, Popat U, Carrum G, Champlin RE, et al. Allogeneic haematopoietic cell transplantation for myelofibrosis in 30 patients 60–78 years of age. Br J Haematol. 2011;153(1):76–82.

    Article  PubMed  PubMed Central  Google Scholar 

  76. Passamonti F, Cervantes F, Vannucchi AM, Morra E, Rumi E, Pereira A, et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood. 2010;115(9):1703–8.

    Article  CAS  PubMed  Google Scholar 

  77. Gangat N, Caramazza D, Vaidya R, George G, Begna K, Schwager S, et al. DIPSS plus: a refined dynamic international prognostic scoring system for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol. 2011;29(4):392–7.

    Article  PubMed  Google Scholar 

  78. Tefferi A, Guglielmelli P, Lasho TL, Gangat N, Ketterling RP, Pardanani A, et al. MIPSS70+Version 2.0: mutation and karyotype-enhanced international prognostic scoring system for primary myelofibrosis. J Clin Oncol. 2018;36(17):1769.

    Article  PubMed  Google Scholar 

  79. Tefferi A, Guglielmelli P, Nicolosi M, Mannelli F, Mudireddy M, Bartalucci N, et al. GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis. Leukemia. 2018;32(7):1631–42.

    Article  PubMed  PubMed Central  Google Scholar 

  80. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. Cancer J Clin. 2020;70(1):7–30.

    Article  Google Scholar 

  81. Cowan AJ, Allen C, Barac A, Basaleem H, Bensenor I, Curado MP, et al. Global burden of multiple myeloma: a systematic analysis for the global burden of disease study 2016. JAMA Oncol. 2018;4(9):1221–7.

    Article  PubMed  PubMed Central  Google Scholar 

  82. Vuyyala SCK, Fu P, et al. The prognostic factors for early fatal outcome in patients with multiple myeloma. Blood. 2019;134(Suppl 1):270.

    Article  Google Scholar 

  83. Palumbo ABS, Mateos MV, Larocca A, Facon T, Kumar SK, Offidani M, McCarthy P, Evangelista A, Lonial S, Zweegman S, Musto P, Terpos E, Belch A, Hajek R, Ludwig H, Stewart AK, Moreau P, Anderson K, Einsele H, Durie BG. Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report. Blood. 2015;125:2068–74.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  84. Engelhardt M, Domm A-S, Dold SM, Ihorst G, Reinhardt H, Zober A, et al. A concise revised myeloma comorbidity index as a valid prognostic instrument in a large cohort of 801 multiple myeloma patients. Haematologica. 2017;102(5):910–21.

    Article  PubMed  PubMed Central  Google Scholar 

  85. Facon T, Dimopoulos MA, Meuleman N, Belch A, Mohty M, Chen WM, et al. A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial. Leukemia. 2020;34(1):224–33.

    Article  PubMed  Google Scholar 

  86. Stege CAM, van der Holt B, Dinmohamed AG, Sonneveld P, Levin M-D, van de Donk NWCJ, et al. Validation of the FIRST simplified frailty scale using the ECOG performance status instead of patient-reported activities. Leukemia. 2020;34(7):1964–6.

    Article  PubMed  Google Scholar 

  87. Milani P, Rajkumar SV, Merlini G, Kumar S, Gertz MA, Palladini G, et al. N-terminal fragment of the type-B natriuretic peptide (NT-proBNP) contributes to a simple new frailty score in patients with newly diagnosed multiple myeloma. Am J Hematol. 2016;91(11):1129–34.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  88. Cook G, Royle K-L, Pawlyn C, Hockaday A, Shah V, Kaiser MF, et al. A clinical prediction model for outcome and therapy delivery in transplant-ineligible patients with myeloma (UK Myeloma Research Alliance Risk Profile): a development and validation study. Lancet Haematol. 2019;6(3):E154–66.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Division of Hematology-Oncology, University of Washington-Fred Hutchinson Cancer Research Center, Seattle, WA, USA

    Debbie C. Jiang

  2. Division of Hematology, The University of North Carolina at Chapel Hill, Chapel Hill, United States

    Shakira J. Grant

  3. Division of Hematology and Hematologic Malignancies, Beth Israel Deaconess Medical Center, Boston, United States

    Debbie C. Jiang

Authors
  1. Shakira J. Grant
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Debbie C. Jiang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Shakira J. Grant .

Editor information

Editors and Affiliations

  1. California Association of Long Term Care Medicine, Newbury Park, CA, USA

    Michael R. Wasserman

  2. Betty Irene Moore School of Nursing, University of California, Davis, Sacramento, CA, USA

    Debra Bakerjian

  3. Department of Clinical Pharmacy, University of Colorado School of Pharmacy and Pharmaceutical Sciences, Aurora, CO, USA

    Sunny Linnebur

  4. Division of Geriatrics, SUNY Upstate Medical University, Syracuse, NY, USA

    Sharon Brangman

  5. Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy

    Matteo Cesari

  6. Section of Geriatric Medicine, Division of Internal Medicine, Department of Medicine, Cedars-Sinai, Beverly Hills, CA, USA

    Sonja Rosen

Section Editor information

  1. California Association of Long Term Care Medicine, Newbury Park, CA, USA

    Michael R. Wasserman M.D., CMD

  2. Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy

    Matteo Cesari MD, PhD

  3. Geriatric Unit, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy

    Matteo Cesari MD, PhD

Rights and permissions

Reprints and permissions

Copyright information

© 2023 Springer Nature Switzerland AG

About this entry

Check for updates. Verify currency and authenticity via CrossMark

Cite this entry

Grant, S.J., Jiang, D.C. (2023). Hematologic Disorders. In: Wasserman, M.R., Bakerjian, D., Linnebur, S., Brangman, S., Cesari, M., Rosen, S. (eds) Geriatric Medicine. Springer, Cham. https://doi.org/10.1007/978-3-030-01782-8_53-1

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-01782-8_53-1

  • Received:

  • Accepted:

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-01782-8

  • Online ISBN: 978-3-030-01782-8

  • eBook Packages: Springer Reference MedicineReference Module Medicine

Publish with us

Policies and ethics

Search

Navigation